Cryoport Reports $44.2 Million Revenue in Q3 2025, Net Loss of $6.9 Million

Cryoport, Inc. reported a total revenue of $44.2 million for the third quarter of 2025, marking a 15.4% increase from $38.3 million in the same period of 2024. The growth was driven by a 15.9% rise in Life Sciences Services revenue, which reached $24.3 million, and a 14.9% increase in Life Sciences Products revenue, totaling $20.0 million. The company's gross margin improved to 48.2%, up from 45.5% in the prior year, reflecting effective cost management despite a 9.7% increase in total cost of revenue, which amounted to $22.9 million.

In terms of profitability, Cryoport reported a net loss of $6.9 million for the quarter, a significant decline from a net income of $0.8 million in Q3 2024. This shift was attributed to a lack of gains from extinguished debt, which had contributed $17.3 million to the previous year's results. The loss from continuing operations was $6.7 million, compared to a profit of $3.9 million in the prior year. The company also noted a decrease in investment income and an increase in other expenses, which further impacted the bottom line.

Strategically, Cryoport completed the divestiture of its CRYOPDP business to DHL for $133 million in June 2025, a move aimed at enhancing its focus on core operations and expanding its service offerings in the EMEA and APAC regions. This divestiture has been classified as discontinued operations, and the results from this segment have been excluded from the current and prior periods' continuing operations. The company continues to support 745 clinical trials globally, with 83 in Phase 3, indicating a strong position in the regenerative medicine market.

Operationally, Cryoport's customer base and engagement metrics have shown positive trends, with a notable increase in clinical trials supported compared to the previous year. The company reported a total of 745 clinical trials as of September 30, 2025, up from 691 a year earlier. The demand for its BioLogistics Solutions and BioStorage/BioServices has driven revenue growth, particularly in the commercial cell and gene therapy sectors. The company also reported a significant increase in its cash and cash equivalents, which rose to $255.8 million, up from $34.1 million at the end of 2024, providing a solid liquidity position for future investments.

Looking ahead, Cryoport anticipates continued growth in its Life Sciences Services and Products segments, driven by the increasing demand for temperature-controlled supply chain solutions in the life sciences sector. The company plans to leverage its enhanced financial position post-divestiture to invest in new technologies and geographic expansion, aiming to solidify its leadership in the market. However, management acknowledges the potential challenges posed by inflationary pressures and market conditions that could impact future performance.